| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.QAI.0000159668.80207.5B |
| P8608 | Fatcat ID | release_axaoxdkag5h25gsmbdvkgkxd3i |
| P698 | PubMed publication ID | 16249709 |
| P50 | author | Max Essex | Q6794729 |
| Ibou Thior | Q86710900 | ||
| Tendani Gaolathe | Q91908938 | ||
| Andrew Mujugira | Q92489544 | ||
| Ndwapi Ndwapi | Q92727538 | ||
| Richard Marlink | Q117265891 | ||
| Peter Cardiello | Q125332775 | ||
| P2093 | author name string | Soyeon Kim | |
| Ava Avalos | |||
| C William Wester | |||
| Chris Vanderwarker | |||
| Hermann Bussmann | |||
| Howard Moffat | |||
| Lesego Busang | |||
| Trevor F Peter | |||
| Onalethata Johnson | |||
| Patson Mazonde | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Botswana | Q963 |
| HIV | Q15787 | ||
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 336-343 | |
| P577 | publication date | 2005-11-01 | |
| P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
| P1476 | title | Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana | |
| P478 | volume | 40 |
| Q37415603 | Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges |
| Q39805282 | Adverse Events in HIV-Infected Persons Receiving Antiretroviral Drug Regimens in a Large Urban Slum in Nairobi, Kenya, 2003-2005. |
| Q36325668 | Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study. |
| Q35938138 | Antiretroviral therapy in the Malawi police force: access to therapy and treatment outcomes |
| Q37605850 | Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy |
| Q36839894 | Antiretroviral treatment strategies in resource-limited settings |
| Q37692981 | Assessing the Impact of Airborne Outreach to Build Clinical Capacity in Rural Botswana |
| Q39902009 | Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso |
| Q35008574 | Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai |
| Q36273986 | Community-based ART distribution system can effectively facilitate long-term program retention and low-rates of death and virologic failure in rural Uganda |
| Q36932005 | Current understanding of HIV-associated neurocognitive disorders pathogenesis |
| Q37174438 | Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda |
| Q35767307 | Development and validation of a clinical score for prognosis stratification in patients requiring antiretroviral therapy in sub-Saharan Africa: a prospective open cohort study |
| Q39049420 | Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives |
| Q37265947 | Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa |
| Q37215053 | Early mortality and cause of deaths in patients using HAART in Brazil and the United States |
| Q34119037 | Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis |
| Q37262671 | Effect of high-dose vs standard-dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial |
| Q34592711 | Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review |
| Q37165025 | Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures -- a meta-analysis. |
| Q33782796 | Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program |
| Q33869315 | Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program |
| Q33718364 | Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy |
| Q35938490 | Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi |
| Q33282786 | Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review |
| Q42552743 | HIV immune reconstitution syndrome in sub-Saharan Africa |
| Q35780728 | Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda |
| Q43940258 | High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania |
| Q39795649 | High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda |
| Q46526697 | High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe |
| Q34604679 | Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria |
| Q34240160 | Immunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in Mozambique |
| Q37127890 | Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique |
| Q35170385 | Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia |
| Q34087372 | Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya |
| Q93135228 | Incidence and determinants of mortality among adult HIV infected patients on second-line antiretroviral treatment in Amhara region, Ethiopia: a retrospective follow up study |
| Q38452483 | Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. |
| Q34614542 | Increasing transfers-out from an antiretroviral treatment service in South Africa: patient characteristics and rates of virological non-suppression |
| Q35917573 | Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India |
| Q50055415 | Inpatient mortality rates during an era of increased access to HIV testing and ART: A prospective observational study in Lilongwe, Malawi |
| Q42223276 | Leveraging rapid implementation of an HIV treatment policy to reduce confounding in observational analysis of antiretroviral outcomes |
| Q33638969 | Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study |
| Q37084674 | Malawi's contribution to "3 by 5": achievements and challenges |
| Q37641584 | Minimum infective dose of HIV for parenteral dosimetry |
| Q37326881 | Mortality and loss to follow-up among HAART initiators in rural South Africa. |
| Q34155253 | Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies |
| Q35014739 | Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials |
| Q34927469 | Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana |
| Q33302944 | Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review |
| Q40798485 | Patients with advanced HIV type 1 infection initiating antiretroviral therapy in Botswana: treatment response and mortality. |
| Q40247957 | Patterns and Predictors of First-Line Antiretroviral Therapy Modification in HIV-1-Infected Adults in a Large Urban Outpatient Cohort in Nigeria. |
| Q39306109 | Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi |
| Q28472810 | Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy |
| Q33596118 | Predictors of Survival among Adult Ethiopian Patients in the National ART Program at Seven University Teaching Hospitals: A Prospective Cohort Study |
| Q36112621 | Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study |
| Q33330114 | Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania |
| Q33279183 | Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa |
| Q37578947 | Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants |
| Q34732899 | Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial |
| Q37726594 | Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria |
| Q35788262 | Retention in HIV Care and Predictors of Attrition from Care among HIV-Infected Adults Receiving Combination Anti-Retroviral Therapy in Addis Ababa |
| Q34395892 | Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy |
| Q37176672 | Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana |
| Q40798969 | Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana |
| Q35164547 | Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy |
| Q58979534 | Staying the course |
| Q37653953 | The Immunological Response of Hiv-Positive Patients Initiating Haart at the Komfo Anokye Teaching Hospital, Kumasi, Ghana |
| Q46760752 | The incidence of first-line antiretroviral treatment changes and related factors among HIV-infected sex workers in Nairobi, Kenya |
| Q33852863 | Treatment outcomes in a decentralized antiretroviral therapy program: a comparison of two levels of care in north central Nigeria |
| Q37084876 | True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi |
| Q47139255 | Tuberculosis and lactic acidosis as causes of death in adult patients from a regional hospital in Johannesburg. |
| Q33479343 | Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania |
| Q37698748 | Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review |
| Q36571433 | What happens to patients on antiretroviral therapy who transfer out to another facility? |
Search more.